AcousticaBio

AcousticaBio has developed a proprietary platform that enables the formulation of ultra-high concentration biologic drugs—including monoclonal antibodies, ADCs, bispecifics, and fusion proteins—into stable microparticle suspensions suitable for subcutaneous injection. This approach addresses challenges related to viscosity and stability at high concentrations, potentially allowing more therapies to be delivered via convenient subcutaneous routes rather than intravenous infusion. The company’s process is gentle and versatile, minimizing product loss and aggregation while improving patient experience through easier self-administration. Clinical results are not available as the company provides enabling technology rather than direct therapeutics.